Developer of the Only Non-Hormonal Therapy for HSDD in Women Announces S1P-205, the Only Therapy for HSDD in Men Jersey City, NJ — May 14, 2012 —S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder…
Emerging Women’s Sexual Health BioPharma Strengthens Position in Marketplace with New Additions Jersey City, NJ — April 24, 2012 — S1 Pharmaceuticals, Inc., a developer of therapeutics for disorders of women’s sexual health, announced today an executive management addition and…
Emerging Women’s Sexual Health BioPharma Strengthens Position in Marketplace with New Additions Jersey City, NJ — March 8, 2012 — S1 Pharmaceuticals, Inc., a developer of therapeutics for disorders of women’s sexual health, announced today an executive management addition and…
60-Patient National Phase I-b Clinical Trial to Begin in 2012 Jersey City, NJ — February 20, 2012 — S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug…
Industry Thought Leaders Strengthen S1 Position in Women’s Sexual Health Niche Jersey City, NJ — October 24, 2011 — S1 Pharmaceuticals, Inc. (S1) today announced that it has appointed Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to…